UBS Group’s Greenwich LifeSciences GLSI Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | $16.7K | Sell |
1,845
-1,351
| -42% | -$12.3K | ﹤0.01% | 7245 |
|
|
2025
Q1 | $30.5K | Sell |
3,196
-3,361
| -51% | -$32.1K | ﹤0.01% | 6636 |
|
|
2024
Q4 | $73.6K | Buy |
6,557
+3,750
| +134% | +$42.1K | ﹤0.01% | 5845 |
|
|
2024
Q3 | $40.3K | Buy |
2,807
+1,000
| +55% | +$14.4K | ﹤0.01% | 5756 |
|
|
2024
Q2 | $31.2K | Buy |
1,807
+1,405
| +350% | +$24.3K | ﹤0.01% | 5884 |
|
|
2024
Q1 | $8.02K | Sell |
402
-1,438
| -78% | -$28.7K | ﹤0.01% | 6177 |
|
|
2023
Q4 | $19.4K | Buy |
1,840
+1,839
| +183,900% | +$19.3K | ﹤0.01% | 5918 |
|
|
2023
Q3 | $9 | Sell |
1
-227
| -100% | -$2.04K | ﹤0.01% | 8081 |
|
|
2023
Q2 | $2.2K | Buy |
228
+227
| +22,700% | +$2.19K | ﹤0.01% | 6711 |
|
|
2023
Q1 | $14 | Sell |
1
-723
| -100% | -$10.1K | ﹤0.01% | 8343 |
|
|
2022
Q4 | $11K | Sell |
724
-1,085
| -60% | -$16.5K | ﹤0.01% | 7254 |
|
|
2022
Q3 | $17K | Buy |
1,809
+939
| +108% | +$8.82K | ﹤0.01% | 6497 |
|
|
2022
Q2 | $7K | Buy |
870
+45
| +5% | +$362 | ﹤0.01% | 7445 |
|
|
2022
Q1 | $16K | Sell |
825
-1,939
| -70% | -$37.6K | ﹤0.01% | 6691 |
|
|
2021
Q4 | $67K | Sell |
2,764
-1,546
| -36% | -$37.5K | ﹤0.01% | 5569 |
|
|
2021
Q3 | $168K | Buy |
4,310
+3,550
| +467% | +$138K | ﹤0.01% | 4396 |
|
|
2021
Q2 | $34K | Buy |
760
+451
| +146% | +$20.2K | ﹤0.01% | 5719 |
|
|
2021
Q1 | $11K | Sell |
309
-571
| -65% | -$20.3K | ﹤0.01% | 6829 |
|
|
2020
Q4 | $32K | Buy |
880
+603
| +218% | +$21.9K | ﹤0.01% | 5570 |
|
|
2020
Q3 | $1K | Buy |
+277
| New | +$1K | ﹤0.01% | 6903 |
|